Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters









Database
Language
Publication year range
1.
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
Juretzka, M; Hensley, M L; Tew, W; Konner, J; Aghajanian, C; Leitao, M; Iasonos, A; Soslow, R; Park, K; Sabbatini, P.
Eur J Gynaecol Oncol ; 29(6): 568-72, 2008.
Article in English | MEDLINE | ID: mdl-19115680

ABSTRACT

PURPOSE OF INVESTIGATION: To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). METHODS: 35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally. RESULTS: One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS. CONCLUSIONS: Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.


Subject(s)
Fallopian Tube Neoplasms/drug therapy , Neoplasm Recurrence, Local/prevention & control , Neoplasms, Glandular and Epithelial/drug therapy , Ovarian Neoplasms/drug therapy , Peritoneal Neoplasms/drug therapy , Piperazines/administration & dosage , Protein Kinase Inhibitors/administration & dosage , Pyrimidines/administration & dosage , Administration, Oral , Adult , Aged , Benzamides , Disease-Free Survival , Fallopian Tube Neoplasms/mortality , Female , Humans , Imatinib Mesylate , Middle Aged , Neoplasms, Glandular and Epithelial/mortality , Ovarian Neoplasms/mortality , Peritoneal Neoplasms/mortality , Piperazines/adverse effects , Protein Kinase Inhibitors/adverse effects , Pyrimidines/adverse effects
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL